Long-Term Experience and Safety of Transitioning from Subcutaneous Treprostinil to Oral Selexipag in the High-Risk Pulmonary Hypertension Patient: A Case Report
Acta Cardiol Sin
.
2023 May;39(3):492-496.
doi: 10.6515/ACS.202305_39(3).20230130A.
Authors
Yung-Hsiang Ting
1
,
Min-Wei Yu
2
,
Yih-Jer Wu
1
3
,
Shu-Hao Wu
1
Affiliations
1
Pulmonary Hypertension Interventional Medicine, Cardiovascular Center, Department of Internal Medicine, MacKay Memorial Hospital, Taipei.
2
Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung.
3
Department of Medicine, and Institute of Biomedical Sciences, MacKay Medical College, New Taipei City, Taiwan.
PMID:
37229336
PMCID:
PMC10203720
DOI:
10.6515/ACS.202305_39(3).20230130A
No abstract available
Keywords:
Heart failure; Hemodynamics; Pulmonary hypertension.